Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metabolomic Analytical Approach Identifies Multiple Neonatal Errors of Metabolism Disorders

By LabMedica International staff writers
Posted on 19 Jul 2021
A recent paper demonstrated that an untargeted metabolomics analytical approach could identify many more neonatal disorders caused by inborn errors of metabolism (IEM) than could be found by traditional methods.

With expanded newborn screening becoming increasingly available, a broader approach to primary screening for IEMs is needed. More...
In this regard, investigators at Baylor College of Medicine (Houston, TX, USA) examined whether untargeted metabolomic profiling could significantly increase the diagnostic rate of screening for IEMs compared with the traditional metabolic screening approach. Thus, the traditional trio testing of plasma amino acids, plasma acylcarnitine profiling, and urine organic acids was contrasted with advanced liquid chromatography–coupled mass spectrometry analysis of metabolites.

The clinical metabolomics approach is capable of detecting multiple metabolites with varying chemical properties in a single test for the global analysis of perturbations in biochemical pathways that would otherwise require multiple targeted tests. Using this approach, small molecules ranging from 75-1000 Daltons were extracted from plasma derived from an EDTA whole blood sample using an 80% methanol solution containing four extraction efficiency standards. The clarified supernatant solution was analyzed by one of two different liquid chromatography–coupled mass spectrometry configurations, depending on the date the sample was received in the laboratory.

For this study, data was generated from 4464 clinical samples received from 1483 unrelated families that had been referred for trio testing of plasma amino acids, plasma acylcarnitine profiling, and urine organic acids and from 2000 consecutive plasma samples from 1807 unrelated families received for clinical metabolomic screening.

Results revealed that of 1483 cases screened by the traditional approach, 912 patients (61.5%) were male and 1465 (98.8%) were pediatric. A total of 19 families were identified with IEMs, resulting in a 1.3% diagnostic rate. A total of 14 IEMs were detected, including three conditions not included in the Recommended Uniform Screening Panel for NBS (newborn screening). Of the 1807 unrelated families undergoing plasma metabolomic profiling, 1059 patients (58.6%) were male, and 1665 (92.1%) were pediatric. Screening identified 128 unique cases with IEMs, giving an overall diagnostic rate of 7.1%. In total, 70 different metabolic conditions were identified, including 49 conditions not presently included on the Recommended Uniform Screening Panel for NBS.

Overall, clinical metabolomics supported diagnosis in 7.1% of cases, providing an approximately six-fold higher diagnostic rate in screening for IEMs and identifying more disorders and more disease types compared with the traditional screening approach.

"Currently, newborn screening is conducted in every infant born in the U.S. to check for serious but rare health conditions at birth. Screening includes blood, hearing, and heart tests," said senior author Dr. Sarah Elsea, professor of molecular and human genetics at Baylor College of Medicine. "While newborn screening in general has improved in the last 10 years, clinically screening for inborn errors of metabolism has not changed substantially in the last 40 to 50 years."

"We developed a clinical test - untargeted metabolomics profiling - that looks at a broader range of metabolic compounds in the blood, therefore screening for many more disorders than the currently used approach," said Dr. Elsea. "In the current study, we compared the standard approach and untargeted metabolomics on their effectiveness identifying metabolic conditions. We are finding individuals with milder forms of a disease are more common in our populations than those with severe forms. Our approach has been quite successful identifying seizure disorders, movement disorders, and autism spectrum disorders. Our analyses have taught us to open our minds to a much greater spectrum of disease, allowing us to improve early diagnosis."

The clinical metabolomics approach for diagnosis of IEMs was published in the July 12, 2021, online edition of the journal JAMA Network Open.

Related Links:
Baylor College of Medicine


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.